61 - Outpatient COVID-19 Therapy with Salim Rezaie, MD

<p class="p1">The treatment of non-hospitalized patients suffering from COVID-19 is a hot topic and constantly changing. Today we have a conversation with <a href= "https://twitter.com/srrezaie?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor"> <span class="s1">Salim Rezaie, MD</span></a> whose dive into this literature couldn’t be much deeper. We discuss which subgroup of patients might benefit from monoclonal antibodies, why the jury is still out on the benefit of ivermectin, the role of inhaled budesonide, and outpatient anticoagulation which hasn’t been studied, but hopefully will be someday.</p> <p class="p1"><strong>Guest Bio:</strong>  Salim Rezaie completed his medical school training at Texas A&M Health Science Center and continued his medical education with a combined Emergency Medicine/Internal Medicine residency at East Carolina University.  He currently works as a community emergency physician at Greater San Antonio Emergency Physicians (GSEP) where he is the director of clinical education.  Salim is the creator and founder of <a href="https://rebelem.com/"><span class= "s1">REBEL EM</span></a> and <a href= "https://rebelem.com/rebel-cast/"><span class="s1">REBEL Cast</span></a>, a free, critical appraisal blog and podcast that tries to cut down knowledge translation gaps of research to bedside clinical practice. Hear more from Salim on <a href= "https://www.stimuluspodcast.com/post/16-the-accumulation-of-marginal-gains-with-salim-rezaie"> <span class="s1">Stimulus #16 Accumulation of Marginal Gains</span></a>.</p> <p class="p1"> </p> <p class="p2"><strong>We Discuss:</strong></p> <p class="p2"> </p> <ul> <li class="p2"><strong>The fact that the best treatment of COVID is prevention through vaccination [2:30];</strong></li> <li class="p2"><strong>The value and purported benefit of monoclonal antibodies [03:21];</strong></li> <li class="p2"><strong>Whether a rapid antibody test would help predict seronegativity [06:30];</strong></li> <li class="p2"><strong>Specifically which monoclonal antibodie